These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7945725)

  • 1. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates.
    Gesson JP; Jacquesy JC; Mondon M; Petit P; Renoux B; Andrianomenjanahary S; Dufat-Trinh Van H; Koch M; Michel S; Tillequin F
    Anticancer Drug Des; 1994 Oct; 9(5):409-23. PubMed ID: 7945725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
    Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
    Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
    Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
    Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide gene therapy using E. coli beta-galactosidase.
    Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
    Heinis C; Alessi P; Neri D
    Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of anthracycline antibiotics suited for tumor-specific activation.
    Azoulay M; Florent JC; Monneret C; Gesson JP; Jacquesy JC; Tillequin F; Koch M; Bosslet K; Czech J; Hoffman D
    Anticancer Drug Des; 1995 Sep; 10(6):441-50. PubMed ID: 7575986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-directed enzyme prodrug therapy.
    Connors TA
    Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145
    [No Abstract]   [Full Text] [Related]  

  • 12. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
    Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
    Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensely cytotoxic anthracycline prodrugs: galactosides.
    Bakina E; Farquhar D
    Anticancer Drug Des; 1999 Dec; 14(6):507-15. PubMed ID: 10834272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
    Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
    Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
    Mauger AB; Burke PJ; Somani HH; Friedlos F; Knox RJ
    J Med Chem; 1994 Oct; 37(21):3452-8. PubMed ID: 7932574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-immolative anthracycline prodrugs for suicide gene therapy.
    Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
    J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.